DR. SAMUEL BRODER, M.D.
Osteopathic Medicine at Honeybee Ln, Bethesda, MD
License number
Maryland D0017618
Category
Osteopathic Medicine
Type
Independent Medical Examiner
Address
Address
8612 Honeybee Ln, Bethesda, MD 20817
Phone
(240) 453-3300
(240) 453-3074 (Fax)
(240) 453-3074 (Fax)
Personal information
See more information about SAMUEL BRODER at radaris.comName
Address
Phone
8612 Honeybee Ln, Bethesda, MD 20817
9309 Sprinklewood Ln, Rockville, MD 20854
9309 Sprinklewood Ln, Potomac, MD 20854
6410 Goldleaf Dr, Bethesda, MD 20817
6011 Woodcrest Ave, Baltimore, MD 21209
Professional information
See more information about SAMUEL BRODER at trustoria.com
Vaccines And Methods For Prevention And Treatment Of Drug-Resistant Hiv-1 And Hepatitis B Virus
Vaccines And Methods For Prevention And Treatment Of Drug-Resistant Hiv-1 And Hepatitis B Virus
US Patent:
2009031, Dec 24, 2009
Filed:
Feb 22, 2006
Appl. No.:
11/816704
Inventors:
Andrew Catanzaro - Washington DC, US
Robert Yarchoan - Bethesda MD, US
Jay A. Berzofsky - Bethesda MD, US
Takahiro Okazaki - Kanagawa, JP
Samuel Broder - Bethesda MD, US
Robert Yarchoan - Bethesda MD, US
Jay A. Berzofsky - Bethesda MD, US
Takahiro Okazaki - Kanagawa, JP
Samuel Broder - Bethesda MD, US
Assignee:
THE GOV'T OF USOA as represented by the SECRETARY OF THE DEPT OF HHS - Rockville MD
International Classification:
A61K 39/21, A61K 39/12, A61K 39/29, C12N 5/00, C07K 7/06, C12N 7/06, A61P 31/18, A61P 31/12, A61P 31/14
US Classification:
4241881, 4241861, 4241891, 435377, 530328, 435238
Abstract:
The present invention provides methods for lowering a viral load of a virus resistant to an antiviral drug by inducing cytotoxic T lymphocytes (CTL) to recognize a predetermined mutated epitope within a viral protein of the drug-resistant virus. CTLs are induced by immunizing a host with a peptide comprising the predetermined mutation. The immunostimulating peptide may be further improved by epitope-enhancement for inducing specific CTLs. The antiviral protection against drug-resistant virus shown by compositions of the present invention and mediated by human HLA-restricted CTL has not been previously achieved.
Method Of Inhibiting Hiv Replication With 2',3'-Dideoxyadenosine
Method Of Inhibiting Hiv Replication With 2',3'-Dideoxyadenosine
US Patent:
5616566, Apr 1, 1997
Filed:
Apr 30, 1993
Appl. No.:
8/056043
Inventors:
Hiroaki Mitsuya - Rockville MD
Samuel Broder - Bethesda MD
Robert Yarchoan - Bethesda MD
Samuel Broder - Bethesda MD
Robert Yarchoan - Bethesda MD
Assignee:
The United States of America as represented by the Department of Health
and Human Services - Washington DC
and Human Services - Washington DC
International Classification:
A61K 3170, C07H 19173, C07H 1920
US Classification:
514 47
Abstract:
A method for inhibiting intracellular replication of HIV in an HIV-infected individual comprising contacting the HIV reverse transcriptase in the HIV-infected cells with 2',3'-dideoxyadenosine-5'-triphosphate whose source is 2',3'-dideoxyadenosine or a pharmaceutically acceptable salt or prodrug thereof.
Immortalized T-Lymphocyte Cell Line For Testing Htlv-Iii Inactivation
Immortalized T-Lymphocyte Cell Line For Testing Htlv-Iii Inactivation
US Patent:
4704357, Nov 3, 1987
Filed:
Sep 30, 1985
Appl. No.:
6/781461
Inventors:
Hiroaki Mitsuya - Rockville MD
Samuel Broder - Bethesda MD
Samuel Broder - Bethesda MD
Assignee:
United States of America as represented by the Department of Health and
Human Services - Washington DC
Human Services - Washington DC
International Classification:
C12N 500, C12N 704, C12Q 118
US Classification:
435 32
Abstract:
This invention is an immortalized T-cell clone, designated ATH8, which is highly sensitive to the cytopathic effect of HTLV-III. The ATH8 T-cell clone is used in mass screening systems to rapidly and easily determine the in vitro capacity of new drugs or other agents to inactivate or inhibit HTLV-III or related cytopathic retroviruses.
Cell Line Producing Human Monoclonal Antibody Which Binds To Htlv-I Producing Cells
Cell Line Producing Human Monoclonal Antibody Which Binds To Htlv-I Producing Cells
US Patent:
4722888, Feb 2, 1988
Filed:
Mar 29, 1985
Appl. No.:
6/717613
Inventors:
Samuel Broder - Bethesda MD
Shuzo Matsushita - Rockville MD
Shuzo Matsushita - Rockville MD
Assignee:
United States of America as represented by the Department of Health and
Human Services - Washington DC
Human Services - Washington DC
International Classification:
C12Q 170, G01N 3353, G01N 33577, A61K 3942
US Classification:
435 5
Abstract:
The present invention is an immortalized B-cell line which produces a human monoclonal antibody IgG-Kk which specifically binds to the envelope antigen of human T-cell leukemia virus Type 1 (HTLV-I). This monoclonal antibody is useful as a diagnostic reagent by binding to the antigen specifically expressed on the surface of HTLV producing cells. Furthermore, this monoclonal antibody is useful as a therapeutic reagent, in combination with complement, for the lysis of HTLV-1 producing cells.
Pyrimidine And Purine 1,2-Butadiene-4-Ols As Anti-Retroviral Agents
Pyrimidine And Purine 1,2-Butadiene-4-Ols As Anti-Retroviral Agents
US Patent:
4935427, Jun 19, 1990
Filed:
Dec 31, 1987
Appl. No.:
7/140269
Inventors:
Samuel Broder - Bethesda MD
Seiji Hayashi - Bethesda MD
Hiroaki Mitsuya - Rockville MD
Jiri Zemlicka - Warren MI
Shashikant Phadtare - Detroit MI
Seiji Hayashi - Bethesda MD
Hiroaki Mitsuya - Rockville MD
Jiri Zemlicka - Warren MI
Shashikant Phadtare - Detroit MI
Assignee:
The United States of America as represented by the Department of Health
and Human Services - Washington DC
and Human Services - Washington DC
International Classification:
A61K 3152, A61K 31505, C07D47334, C07D23947
US Classification:
514261
Abstract:
Compounds which are active against retroviruses have the following formula
HOH. sub. 2 C--CH. dbd. C. dbd. CH--B
wherein B is a purine or pyrimidine heterocyclic ring which is preferably selected from the group consisting of cytosine, 5-halo substituted cytosine, 5-alkyl substituted cytosine, 6-aminopurine, 2,6-diaminopurine, 6-hydroxypurine, 2-amino-6-hydroxypurine, 3-deazapurines, 7-deazapurines, 8-azapurines, and 6-azapyrimidines.
Treatment Of Retroviral Induced Dementia By Administration Of 2',3'-Dideoxyinosine
Treatment Of Retroviral Induced Dementia By Administration Of 2',3'-Dideoxyinosine
US Patent:
5376642, Dec 27, 1994
Filed:
Mar 1, 1993
Appl. No.:
8/026188
Inventors:
Robert Yarchoan - Bethesda MD
Hiroaki Mitsuya - Rockville MD
Samuel Broder - Bethesda MD
Hiroaki Mitsuya - Rockville MD
Samuel Broder - Bethesda MD
Assignee:
The United States of America as represented by the Department of Health
and Human Services - Washington DC
and Human Services - Washington DC
International Classification:
A61K 3170
US Classification:
514 45
Abstract:
A preferred method and dosages for treatment of retrovirus-induced dementia by the administration of 2',3'-dideoxyinosine(ddI) is disclosed.
Antiviral Compositions And Methods
Antiviral Compositions And Methods
US Patent:
4879277, Nov 7, 1989
Filed:
Aug 11, 1987
Appl. No.:
7/084054
Inventors:
Hiroaki Mitsuya - Rockville MD
Samuel Broder - Bethesda MD
Samuel Broder - Bethesda MD
Assignee:
The United States of America as represented by the Department of Health
and Human Services - Washington DC
and Human Services - Washington DC
International Classification:
A61K 3170, C07D47316
US Classification:
514 49
Abstract:
Compositions containing 2',3'-dideoxycytidine and its triphosphates for use in treating retroviral infections including acquired immune deficiency syndrome (AIDS) are disclosed with preferred methods of treatment which provide protection against cytophatic effects of human immunodeficiency virus (HIV).
Treatment Of Human Retroviral Infections With 2',3'-Dideoxyinosine Alone And In Combination With Other Antiviral Compounds
Treatment Of Human Retroviral Infections With 2',3'-Dideoxyinosine Alone And In Combination With Other Antiviral Compounds
US Patent:
5026687, Jun 25, 1991
Filed:
Jan 3, 1990
Appl. No.:
7/460490
Inventors:
Robert Yarchoan - Bethesda MD
Hiroaki Mitsuya - Rockville MD
Samuel Broder - Bethesda MD
Hiroaki Mitsuya - Rockville MD
Samuel Broder - Bethesda MD
Assignee:
The United States of America as represented by the Department of Health
and Human Services - Washington DC
and Human Services - Washington DC
International Classification:
A61K 3170
US Classification:
514 45
Abstract:
A preferred method and dosages for the short and long-term treatment of human retroviral infections, or retroviral-like infections, including acquired immunodeficiency syndrome (AIDS) and other manifestations of human immunodeficiency virus (HIV) infection, with 2',3'-dideoxyinosine (ddl) are disclosed, along with a protocol for halting and restarting 2',3'-dideoxyinosine to minimize certain side effects.
Method Of Monitoring Anti-Tumor Activity Of An Hdac Inhibitor
Method Of Monitoring Anti-Tumor Activity Of An Hdac Inhibitor
US Patent:
2008024, Oct 9, 2008
Filed:
Oct 7, 2005
Appl. No.:
11/664885
Inventors:
Kathryn E. Bass - San Francisco CA, US
Samuel E. Broder - Bethesda MD, US
Peter R. Young - San Francisco CA, US
Samuel E. Broder - Bethesda MD, US
Peter R. Young - San Francisco CA, US
Assignee:
Pharmacyclics, Inc. - Sunnyvale CA
International Classification:
G01N 33/53, G01N 33/68, C12Q 1/02
US Classification:
435 792, 436 86, 435 29
Abstract:
The present invention relates to the method of determining the anti-tumor activity of a histone deacetylase inhibitor by measuring the phosphorylation of the histone variant H2AX or the level of cytokeratin-18 fragment aa 387-397.
Therapeutic Application Of Dideoxycytidinene
Therapeutic Application Of Dideoxycytidinene
US Patent:
4963533, Oct 16, 1990
Filed:
Oct 24, 1986
Appl. No.:
6/922957
Inventors:
Erik D. A. de Clercq - Leuven, BE
Piet A. M. M. Herdewijn - Kessel-Lo, BE
Samuel Broder - Bethesda MD
Jan M. R. Balzarini - Rockville MD
Piet A. M. M. Herdewijn - Kessel-Lo, BE
Samuel Broder - Bethesda MD
Jan M. R. Balzarini - Rockville MD
Assignee:
Stichting Rega VZW (REGA) - Louvain
The Government of the United States of America - Washington DC
The Government of the United States of America - Washington DC
International Classification:
A61K 3170
US Classification:
514 49
Abstract:
The present invention relates to a composition containing the compound 2', 3'-dideoxycytidinene which has an antiviral effect against human immunodeficiency virus (HIV) and may therefore be used as a therapeutic agent for the treatment of AIDS and AIDS related diseases.